DDInter675 DDInter280
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. The FDA withdrew its approval for the use of all parenteral dosage form drug products containing esmolol hydrochloride that supply 250 milligrams/milliliter of concentrated esmolol per 10-milliliter ampule. Other esmolol formulations are still available for use.
Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus , [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes . Cardiovascular disease is the most common cause of death in these patients .
Esmolol {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Esmolol {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Unspecified disorder of skin and subcutaneous tissue {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Esmolol {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Nervous system disorder {u} (Side Effect) is caused by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Esmolol {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Acebutolol
Acebutolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapagliflozin
Dapagliflozin {u} (Compound) resembles {v} (Compound) Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Metipranolol
Metipranolol {u} (Compound) resembles {v} (Compound) Metoprolol
Metoprolol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Canagliflozin
Esmolol {u} (Compound) resembles {v} (Compound) Pindolol
Pindolol {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Canagliflozin
Esmolol (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Canagliflozin (Compound)
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Esmolol (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Esmolol (Compound) causes Nervous system disorder (Side Effect) and Nervous system disorder (Side Effect) is caused by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Esmolol (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Canagliflozin
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Esmolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Esmolol (Compound) resembles Metipranolol (Compound) and Metipranolol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin
Esmolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Canagliflozin (Compound)